EP300对口腔鳞癌细胞增殖和迁移的影响

doi:10.13591/j.cnki.kqyx.2024.02.002

Abstract

Abstract:

Objective To investigate the expression level of EP300 in oral squamous carcinoma and its effect on the proliferation and migration of oral squamous carcinoma cells. Methods Differential expression of EP300 gene in pan-cancerous tissues and their normal tissues was collected and analysed through online database. The gene and protein expression levels of EP300 in the normal oral squamous epithelial cell line NOK and two different OSCC cell lines HSC3 and UM1 were detected by RT-PCR and Western blot, respectively; the EP300 gene was silenced in HSC3 and UM1 cell lines by plasmid transfection. Cell proliferation ability was detected by plate cloning and CCK-8, and cell migration ability was detected by scratch assay. Results Bioconductivity analysis revealed that EP300 expression was significantly upregulated in HNSC of head and neck tumors compared to paraneoplastic tissues. EP300 gene and protein expression levels were significantly higher in HSC3 and UM1 compared to the NOK group (P<0.05), and EP300 endogenous expression was relatively higher in both HSC3 and UM1 cell lines. CCK-8 proliferation assay and clone formation assay detected that the proliferation ability of HSC3 and UM1 was significantly reduced after EP300 silencing (P<0.05). Cell scratch assay detected that the migration ability of HSC3 and UM1 was significantly reduced after EP300 silencing (P<0.05). Conclusion EP300 was highly expressed in oral squamous carcinoma cell lines HSC3 and UM1, and low expression of EP300 inhibited the proliferation and migration of oral squamous carcinoma cells.

Key words: EP300, oral squamous cell carcinoma, proliferation, migration

CLC Number:

R780.2

WANG Yapei, LUO Yuchun, LIU Wei, LIU Chang, TANG Wanrong. Effect of EP300 on the proliferation and migration of oral squamous carcinoma cells[J]. Stomatology, 2024, 44(2): 88-93.

Figures/Tables 6

Tab.1

Fig.1

Fig.2

Fig.3

Fig.4

Fig.5

References 23

[1]	Liao YH, Chou WY, Chang CW, et al. Chemoprevention of oral cancer:A review and future perspectives[J]. Head Neck, 2023, 45(4):1045-1059. doi: 10.1002/hed.v45.4
[2]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA A Cancer J Clinicians, 2021, 71(1):7-33. doi: 10.3322/caac.v71.1
[3]	Ford PJ, Rich AM. Tobacco use and oral health[J]. Addiction, 2021, 116(12):3531-3540. doi: 10.1111/add.15513 pmid: 33822437
[4]	Ramqvist T, Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma(OSCC)due to human papillomavirus(HPV)infection and aspects of treatment and prevention[J]. Anticancer Res, 2011, 31(5):1515-1519.
[5]	Agrawal A, Civantos FJ, Brumund KT, et al. [Tc-99m]Tilmanocept accurately detects sentinel lymph nodes and predicts node pathology status in patients with oral squamous cell carcinoma of the head and neck:Results of a phase Ⅲ multi-institutional trial[J]. Ann Surg Oncol, 2015, 22(11):3708-3715. doi: 10.1245/s10434-015-4382-x pmid: 25670018
[6]	Sathiyasekar AC, Chandrasekar P, Pakash A, et al. Overview of immunology of oral squamous cell carcinoma[J]. J Pharm Bioallied Sci, 2016, 8(Suppl 1):S8-S12. doi: 10.4103/0975-7406.191974 pmid: 27829737
[7]	Ogryzko VV, Schiltz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases[J]. Cell, 1996, 87(5):953-959. doi: 10.1016/s0092-8674(00)82001-2 pmid: 8945521
[8]	Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development[J]. Genes Dev, 2000, 14(13):1553-1577. doi: 10.1101/gad.14.13.1553
[9]	Kim KB, Kabra A, Kim DW, et al. KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer[J]. Sci Adv, 2022, 8(7):eabl4618. doi: 10.1126/sciadv.abl4618
[10]	Yu YL, Chen M, Zhu H, et al. STAT1 epigenetically regulates LCP2 and TNFAIP2 by recruiting EP300 to contribute to the pathogenesis of inflammatory bowel disease[J]. Clin Epigenetics, 2021, 13(1):127. doi: 10.1186/s13148-021-01101-w
[11]	Van Gils J, Magdinier F, Fergelot P, et al. Rubinstein-taybi syndrome:A model of epigenetic disorder[J]. Genes, 2021, 12(7):968. doi: 10.3390/genes12070968
[12]	Orchard A, Shah F, Prabhu S. Diagnosing OSCC via video[J]. Br Dent J, 2020, 228(12):903-904.
[13]	Madhura MG, Rao RS, Patil S, et al. Advanced diagnostic aids for oral cancer[J]. Dis Mon, 2020, 66(12):101034. doi: 10.1016/j.disamonth.2020.101034
[14]	施雯靖, 潘贤润, 吕哲宇, 等. 口腔鳞状细胞癌遗传变异数据库[J]. 电子科技大学学报, 2022, 51(5):661-667.
[15]	Zhu GM, Pei LJ, Li Y, et al. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients[J]. Aging, 2020, 12(3):2132-2141. doi: 10.18632/aging.v12i3
[16]	Wang LB, Karpova A, Gritsenko MA, et al. Proteogenomic and metabolomic characterization of human glioblastoma[J]. Cancer Cell, 2021, 39(4):509-528. e20. doi: 10.1016/j.ccell.2021.01.006
[17]	Asaduzzaman M, Constantinou S, Min HX, et al. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer[J]. Breast Cancer Res Treat, 2017, 163(3):461-474. doi: 10.1007/s10549-017-4202-z
[18]	Dou CW, Liu ZK, Tu KS, et al. P300 acetyltransferase mediates stiffness-induced activation of hepatic stellate cells into tumor-promoting myofibroblasts[J]. Gastroenterology, 2018, 154(8):2209-2221. e14. doi: S0016-5085(18)30209-9 pmid: 29454793
[19]	Henry RA, Kuo YM, Andrews AJ. Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4[J]. Biochemistry, 2013, 52(34):5746-5759. doi: 10.1021/bi400684q pmid: 23862699
[20]	Choi JR, Lee SY, Shin KS, et al. p300-mediated acetylation increased the protein stability of HIPK₂ and enhanced its tumor suppressor function[J]. Sci Rep, 2017, 7(1):16136. doi: 10.1038/s41598-017-16489-w
[21]	Waddell AR, Huang HJ, Liao DQ. CBP/p300:Critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers[J]. Cancers, 2021, 13(12):2872. doi: 10.3390/cancers13122872
[22]	Cho YA, Hong JS, Choe EJ, et al. The role of p300 in the tumor progression of oral squamous cell carcinoma[J]. J Oral Pathol Med, 2015, 44(3):185-192. doi: 10.1111/jop.2015.44.issue-3
[23]	Krupar R, Watermann C, Idel C, et al. In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation[J]. Sci Rep, 2020, 10(1):9389. doi: 10.1038/s41598-020-66329-7

基因	正向引物	反向引物
EP300	5'-CCTCGTATGCAACAGCCTTCC-3'	5'-CGGGCAGGAAGAACTAGACAT-3'
GAPDH	5'-GGAGTCCACTGGCGTCTTCA-3'	5'-GTCATGAGTCCTTCCACGATACC-3'

Effect of EP300 on the proliferation and migration of oral squamous carcinoma cells

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 23

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	SHEN Xiaojing, LIU Hairong, LI Hua, LI Linlin, WANG Lewei, YUAN Rongtao, GUO Qingyuan, ZHAO Peng. Effects of total flavonoids of rhizomadrynariae on proliferation and apoptosis of alveolar bone osteoblasts during osseointegration of oral implants [J]. Stomatology, 2023, 43(8): 679-685.
[2]	XU Yiping, HUANG Jialing, LIU Zhongbin, YANG Kun, GE Song. Research progress of the relationship between Fusobacterium nucleatum and oral squamous cell carcinoma [J]. Stomatology, 2023, 43(6): 546-551.
[3]	HU Haiyan, GAO Teng, ZHU Zai'ou, DING Xu, WU Yunong, SONG Xiaomeng. Study on the role of CMTM4 in oral squamous cell carcinoma and its mechanism [J]. Stomatology, 2023, 43(6): 481-487.
[4]	YANG Yuemei,SONG Xiaomeng,WU Yunong. Promotion of cell proliferation by Notch1^P1641S mutation through PI3K/Akt activation in OSCC [J]. Stomatology, 2023, 43(5): 393-399.
[5]	XIAO Tao, HE Yijia, ZHU Yaoping, HAO Fengyao, CHEN Yan, WANG Zhiyong. Study on the mechanism of VEGF inducing tolerogenic dendritic cells in oral squamous cell carcinoma [J]. Stomatology, 2023, 43(3): 204-211.
[6]	TONG Xuexi, ZHAO Gang. In vitro study on miR-191-5p targeting TJP1 to regulate the proliferation, invasion and migration of Cal-27 cells [J]. Stomatology, 2023, 43(11): 981-988.
[7]	JI Huan, LI Meng, YAO Enhui, ZHONG Yi, ZHANG Yuyao, WU Heming, LI Bin. Study on the expression of LncRNA LINC00958 in head and neck squamous cell carcinoma [J]. Stomatology, 2023, 43(11): 968-974.
[8]	XIAO Jinzhi, YU Wei, ZHANG Hao. Berberine hydrochloride inhibits the proliferation of oral squamous cell carcinoma by regulating autophagy [J]. Stomatology, 2023, 43(10): 889-893.
[9]	GAO Zhen,HOU Ruikai,SONG Suocheng,RUAN Jianping. Effect of calcium on biological properties of the ameloblast ALC [J]. Stomatology, 2023, 43(1): 39-45.
[10]	WANG Ting, DU Lingqian. Effects of Ghrelin on proliferation and apoptosis of periodontal ligament stem cells [J]. Stomatology, 2022, 42(8): 681-687.
[11]	MA Ping, CHENG Luyao, JIN Wulong, WANG Ning, ZHAI Rongping. Expression level and biological function of NCAPD2 in oral squamous cell carcinoma [J]. Stomatology, 2022, 42(8): 688-693.
[12]	HOU Yiming, LI Na, YU Wenqian, CHEN Lei. Research progress of histone modification in oral squamous cell carcinoma [J]. Stomatology, 2022, 42(7): 650-654.
[13]	WANG Jinxin, YI Jie, DING Yujie, ZHONG Yi, SUN Zhida. Expression and role of Claudin-7 in oral squamous cell carcinoma [J]. Stomatology, 2022, 42(7): 604-608.
[14]	AINIWAER Ailimaierdan, HUOJIA Muhetaer, WANG Ling. The effect and primary mechanism of transforming growth factor-β3 on the proliferation and osteogenic capability of osteoblasts [J]. Stomatology, 2022, 42(6): 501-507.
[15]	GUO Zhichen, JING Sili, HU Xiaoyi, ZHANG Zhou, CUI Hao, NA Sijia. Effect of smoking and drinking exposure history on prognosis of patients with oral squamous cell carcinoma at different ages [J]. Stomatology, 2022, 42(6): 521-524.